Auction of Treasury Bills on 15 March 2023
The treasury bills for sale have the following stock exchange codes:
| Name | Stock exchange code | Maturity |
| DGTB 23 / II | 98-18932 | 1 June 2023 |
| DGTB 23 / III | 98-19070 | 1 September 2023 |
The sale will settle on 17 March 2023 at the stop-rate for each serie. In case of bid on stop-rate a pro-rata ratio may occur.
The deadline for bidding is 10.15 on the day of the auction.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics1.5.2024 14:01:00 CEST | Press release
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO. Rachelle Jacques will step down as Akari’s Chief Executive Officer effective today. Melissa Bradford-Klug will step down as Akari’s Chief Operating Officer effective today. In connection with Ms. Jacques’ departure, Akari’s board of directors (the “Board”) has appointed Dr. Patel as Interim Chief Executive Officer. Dr. Patel has served as a member of the Board since December 2023. “I am honored to be appointed interim CEO by the Akari Board of Directors. My immediate goals are timely completion of the previously announced merger between Akari Therapeutics and Peak Bio, implementation of the portfolio prioritization agreed upon by the boards of both companies whil
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity1.5.2024 14:00:00 CEST | Press release
Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak’s ADC (antibody drug conjugate) platform technology and Akari’s PAS-nomacopan Geographic Atrophy (GA) program. Peak’s ADC platform technology is a proprietary technology using antibody plus linker plus Peak Bio toxin with immune modulation and includes a novel pre-clinical ADC candidate targeting TROP-2. Akari’s PAS-nomacopan is a bispecific complement and leukotriene B4 inhibitor with prolonged duration of action b
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates1.5.2024 13:30:00 CEST | Press release
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024. Roluperidone NDA Update On February 27, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its New Drug Application (NDA) for roluperidone (f/k/a MIN-101) for the treatment of negative symptoms in patients with schizophrenia. The Company is in discussions with the FDA regarding the issues and clinical deficiencies raised in the CRL. Phase 1b Clinical Trial (MIN-101C18) In the first quarter of 2024, the Company completed a clinical trial initiated in October 2023 to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of the co-administration of roluperidone and olanzapi
EFRAG Selects Datamaran for Real-time Analysis of the Global ESG Landscape1.5.2024 13:01:17 CEST | Press release
The European Financial Reporting Advisory Group (EFRAG) selects Datamaran as its solution for data-driven ESG governance supporting the development of the European Sustainability Reporting Standards (ESRS) LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- The European Financial Reporting Advisory Group (EFRAG), Europe’s advisory body on financial and sustainability reporting, has chosen Datamaran, the market leader in Smart ESG (Environmental, Social, and Governance) software, as its solution for ESG governance and workflow management to support its research informing the development of the European Sustainability Reporting Standards (ESRS). Talking about the need for Datamaran, Patrick De Cambourg, the Chair of the EFRAG Sustainability Reporting Board, said: “EFRAG's mission is of crucial importance to make reliable and comparable disclosures on all material sustainability matters a reality, and ensure that financial disclosures and sustainability disclosures have the same level of quality and
Plug Secures First International PEM Electrolyzer Certification in Korea1.5.2024 13:00:00 CEST | Press release
Final step completed to enable the commercial sale of Plug electrolyzer systems in Korea LATHAM, N.Y., May 01, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, secured the first international safety and performance certification in Korea for electrolyzer manufacturing, enabling the commercial sale of Plug electrolyzer systems in the Korean market. This achievement was completed through Plug's collaboration with SK E&S in the form of SK Plug HyVerse, a joint venture aimed at advancing the hydrogen sector within the Asian market. Plug achieved certification of its EX425D – a 1 MW (megawatt) PEM (proton exchange membrane) electrolyzer that produces up to 425 kg (kilograms) per day of green hydrogen – to the Korean Gas Safety (KGS) Corporation Standard AH271 for Facility/Technical/Inspection Code for Manufacture of Water Electrolysis Hydrogen Generator. As part of the certification process, KGS appr